Gazala Khan

2.5k total citations · 1 hit paper
42 papers, 1.5k citations indexed

About

Gazala Khan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gazala Khan has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 12 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gazala Khan's work include Pancreatic and Hepatic Oncology Research (18 papers), Cancer Genomics and Diagnostics (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Gazala Khan is often cited by papers focused on Pancreatic and Hepatic Oncology Research (18 papers), Cancer Genomics and Diagnostics (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Gazala Khan collaborates with scholars based in United States, Italy and United Kingdom. Gazala Khan's co-authors include Kannan Thanikachalam, Mark M. Zalupski, Sofía D. Merajver, Diane M. Simeone, Kent A. Griffith, Edward Kim, Joel K. Greenson, John Blau, Ulysses J. Balis and Ronald A. Craig and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Gazala Khan

37 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colorectal Cancer and Nutrition

2019 524 citations Gazala Khan et al. profile →

Peers

Countries citing papers authored by Gazala Khan

Since Specialization

Citations

This map shows the geographic impact of Gazala Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gazala Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gazala Khan more than expected).

Fields of papers citing papers by Gazala Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gazala Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gazala Khan. The network helps show where Gazala Khan may publish in the future.

Co-authorship network of co-authors of Gazala Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Gazala Khan. A scholar is included among the top collaborators of Gazala Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gazala Khan. Gazala Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unlocking the secrets: Exploring the connection between HPV and bladder cancer in Pakistan 2025 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Aneela Javed, (unknown), (unknown), Muhammad Usman, Gazala Khan, (unknown), Sajid Asghar, (unknown)	1
2	A systematic review and meta-analysis on computed tomography angiography mapping for deep inferior epigastric perforator flap breast reconstruction 2025 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Gazala Khan, (unknown), (unknown), Nicola Maggialetti, (unknown), (unknown), Ankur Khajuria	0
3	Laparoscopic Correction of Isthmocele and Cesarean Scar Endometriosis: A Report of a Successful Pregnancy and Treatment of Subfertility 2024 ·Cureus ·(unknown), Gazala Khan, (unknown), (unknown), (unknown)	0
4	NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3. 2024 ·Journal of Clinical Oncology ·Maen Hussein, Gazala Khan, Sreenivasa R Chandana, Roberto Pazo-Cid, Igor Kišš, Javier Gállego, Teresa Macarulla, Christelle de la Fouchardière, Thorsten Oliver Goetze, Andrew Dean, Eileen M. O’Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew Scott Paulson, Tanios Bekaii‐Saab, Shubham Pant, Fiona Maxwell, Davide Melisi	2
5	Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer 2024 ·Biomedicines ·(unknown), Farzan Siddiqui, Gazala Khan, (unknown), David Kwon, Shyam Nyati	3
6	Communal ghettosiation in urban India: A process of informal but systematic segregations 2024 ·GeoJournal ·(unknown), Gazala Khan, (unknown)	0
7	Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). 2023 ·Journal of Clinical Oncology ·Susanna V. Ulahannan, David R. Spigel, Michael Sangmin Lee, Marwan Fakih, Patrick Grierson, Eric S. Christenson, E. Gabriela Chiorean, Darryl Outlaw, Gazala Khan, Chloé E. Atreya, Aparna R. Parikh, Farshid Dayyani, Alexander I. Spira, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, (unknown), Hina Patel, Saswati Hazra, John H. Strickler	1
8	Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan 2021 ·Frontiers in Oncology ·Kenneth H. Yu, Andrew Hendifar, Olatunji B. Alese, (unknown), Maen Abdelrahim, Ethan Burns, Gazala Khan, Paul Cockrum, Rachel H. Bhak, Catherine Nguyen, Maral DerSarkissian, Mei Sheng Duh, Nathan Bahary	5
9	Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer 2020 ·Molecular Therapy — Oncolytics ·Kenneth Barton, Farzan Siddiqui, (unknown), Svend O. Freytag, Gazala Khan, Irina Dobrosotskaya, Munther Ajlouni, Yingshu Zhang, Jingfang Cheng, Benjamin Movsas, David Kwon	43
10	Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer 2018 ·Investigational New Drugs ·Richard S. Finn, Daniel H. Ahn, Milind Javle, Benjamin Tan, Colin D. Weekes, Johanna C. Bendell, Amita Patnaik, Gazala Khan, Daniel A. Laheru, (unknown), Janna Christy‐Bittel, Emma Barrett, Michael B. Sawyer, Tanios Bekaii‐Saab	23
11	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor 2017 ·British Journal of Cancer ·Johanna C. Bendell, Milind Javle, Tanios Bekaii‐Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin Tan, Gazala Khan, Mark M. Zalupski, Jeffrey R. Infante, Suzanne F. Jones, Kyriakos P. Papadopoulos, Anthony W. Tolcher, (unknown), Janna Christy‐Bittel, Emma Barrett, Amita Patnaik	85
12	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer 2015 ·Scientific Reports ·Moumita Chatterjee, Edgar Ben‐Josef, Dafydd G. Thomas, Meredith A. Morgan, Mark M. Zalupski, Gazala Khan, (unknown), Kent A. Griffith, Ching-Shih Chen, Thomas Ludwig, Tanios Bekaii‐Saab, Arnab Chakravarti, Terence M. Williams	85
13	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma 2014 ·Clinical Cancer Research ·Edward Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Khan, John Blau, Ronald A. Craig, Ulysses J. Balis, Mark M. Zalupski, Diane M. Simeone	236
14	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management 2014 ·Cancer Management and Research ·Gazala Khan, Fadi Braiteh, (unknown), Rebecca A. Moss	17
15	Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study 2012 ·International Journal of Radiation OncologyBiologyPhysics ·Jeffrey M. Vainshtein, Matthew J. Schipper, Mark M. Zalupski, Theodore S. Lawrence, Ross A. Abrams, Isaac R. Francis, Gazala Khan, William Leslie, Edgar Ben‐Josef	17
16	A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer 2012 ·International Journal of Radiation OncologyBiologyPhysics ·Edgar Ben‐Josef, Mathew J. Schipper, Isaac R. Francis, Scott Hadley, Randall K. Ten Haken, Theodore S. Lawrence, Daniel P. Normolle, Diane M. Simeone, Christopher J. Sonnenday, Ross A. Abrams, William Leslie, Gazala Khan, Mark M. Zalupski	133
17	Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency 2010 ·Annals of Oncology ·Gazala Khan, Ali Golshayan, Paul Elson, L. Wood, J. Garcia, Ronald M. Bukowski, Brian I. Rini	45
18	New Frontiers in Pancreatic Cancer Research 2010 ·Surgical Oncology Clinics of North America ·Gazala Khan, Marina Pasca di Magliano, Diane M. Simeone	2
19	An Unusual Case of Small Cell Carcinoma of the Anal Canal 2009 ·American Journal of Clinical Oncology ·Gazala Khan, (unknown), Edgar Ben‐Josef, Mark M. Zalupski	3
20	Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency 2007 ·Current Pharmaceutical Design ·Gazala Khan, Sofía D. Merajver	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact